---
title: "Camp4 Therapeutics director Andrew J. Schwab disposes of USD 879,374 in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296653253.md"
description: "Camp4 Therapeutics director Andrew J. Schwab sold 191,865 common shares between Aug. 19-21 via 5AM Ventures VI at weighted average prices ranging from $4.50 to $4.76. Following these transactions, 5AM Ventures VI's holding decreased to 2,433,280 shares."
datetime: "2026-08-21T21:05:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296653253.md)
  - [en](https://longbridge.com/en/news/296653253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296653253.md)
generator: "portal-rs"
---

# Camp4 Therapeutics director Andrew J. Schwab disposes of USD 879,374 in common shares

-   Camp4 Therapeutics director Andrew J. Schwab reported sales totaling 191,865 common shares on Aug. 19-21. \* Sales were executed through 5AM Ventures VI at weighted average prices of $4.76, $4.54, $4.5. \* 5AM Ventures VI’s holding fell to 2,433,280 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001598549-26-000007), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)

## Related News & Research

- [CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells 45,147 Shares](https://longbridge.com/en/news/296653561.md)
- [Camp4 Therapeutics CSO Daniel Tardiff disposes of 1,738 common shares worth $8,272.88](https://longbridge.com/en/news/296415836.md)
- [CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative charge](https://longbridge.com/en/news/295841350.md)
- [Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15](https://longbridge.com/en/news/295017282.md)
- [CAMP4 wins Australia clearance to start Phase 1/2 trial of CMP-002 in SYNGAP1 disorder](https://longbridge.com/en/news/294149424.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**